Automation Workstation for Clinical and Regulatory Lab Compliance
The Fluent Gx Automation Workstation from Tecan is suited for a variety of clinical and regulated laboratory applications.
Tecan, a provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics, announced in a Jan. 25, 2018 press release that it will add the Fluent Gx Automation Workstation for clinical and regulated laboratories to its range of liquid handling solutions in 2018.
According to the company, the workstation solution will meet a host of laboratory needs, including clinical diagnostics, next-generation sequencing, and nucleic acid purification, and provide the advanced process security features required for regulated applications in clinical, GXP, and quality control facilities.
In addition to the liquid handling and workflow features available from related company products, the solution will also include a suite of software features needed to comply with rigorous regulatory requirements, including FDA 21 CFR Part 11, as stated by the company. The Fluent Gx Assurance Software provides full sample tracking capabilities and secure electronic records, together with a laboratory information management system interface, multi-level user management, and electronic signature options to ensure compliant and audit-ready operation.
The solution also includes software utilities to simplify system management. The compliance checker provides rapid, fully automated verification of the integrity of all executable software components, while the data audit tool performs a similar function for electronic records, ensuring data integrity, according to the company.
Source: Tecan
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
